Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UCHL1 | P09936 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.32 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.31 |
| ▸ | PEPD | P12955 | 1/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18589415 | 1.00 | UCHL1 (0.39) | UCHL1CHRM2CHRM1CHRM3CYP1A2 | |
| SCHEMBL6121364 | 1.00 | UCHL1 (0.39) | UCHL1CHRM2CHRM1CHRM3CYP1A2 | |
| SCHEMBL6121361 | 1.00 | UCHL1 (0.39) | UCHL1CHRM2CHRM1CHRM3CYP1A2 | |
| SCHEMBL18589489 | 1.00 | UCHL1 (0.39) | UCHL1CHRM2CHRM1CHRM3CYP1A2 | |
| SCHEMBL25177825 | 0.89 | CYP1A2 (0.46) | UCHL1CHRM2CHRM1CHRM3CYP1A2 | |
| SCHEMBL8135313 | 0.89 | CYP1A2 (0.46) | UCHL1CHRM2CHRM1CHRM3CYP1A2 | |
| SCHEMBL31340622 | 0.89 | CYP1A2 (0.46) | UCHL1CHRM2CHRM1CHRM3CYP1A2 | |
| SCHEMBL13086072 | 0.89 | CYP1A2 (0.46) | UCHL1CHRM2CHRM1CHRM3CYP1A2 | |
| SCHEMBL4305123 | 0.89 | CYP1A2 (0.46) | UCHL1CHRM2CHRM1CHRM3CYP1A2 | |
| SCHEMBL27393745 | 0.89 | CYP1A2 (0.46) | UCHL1CHRM2CHRM1CHRM3CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612414-B2 | Nitrile SUMO inhibitors and uses thereof | CIT THERAPEUTICS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-20240360148-A1 | NITRILE SUMO INHIBITORS AND USES THEREOF | CIT THERAPEUTICS LLC | 2024-10-31 | — | — | US | disclosed |
| EP-4373825-A1 | NITRILE SUMO INHIBITORS AND USES THEREOF | Suvalent Therapeutics, Inc. (US) | 2024-05-29 | — | — | EP | disclosed |
| WO-2023004376-A1 | NITRILE SUMO INHIBITORS AND USES THEREOF | Suvalent Therapeutics, Inc. (US) | 2023-01-26 | — | — | WO | disclosed |
| EP-2374794-B1 | CYCLIC AMINE COMPOUNDS | DAIICHI SANKYO CO LTD (JP) | 2015-11-04 | — | — | EP | disclosed |
| US-20120309811-A1 | P-GLYCOPROTEIN-SPECIFIC NON-COMPETITIVE PEPTIDE AND PEPTIDOMIMETIC MODULATORS | UNIVERSITE CLAUDE BERNARD - LYON 1 (FR) | 2012-12-06 | — | — | US | disclosed |
| US-8173631-B2 | Cyclic amine compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-05-08 | — | — | US | disclosed |
| US-8173631-B2 | Cyclic amine compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-05-08 | — | — | US | disclosed |
| US-20110319468-A1 | CYCLIC AMINE COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-29 | — | — | US | disclosed |
| US-20110319468-A1 | CYCLIC AMINE COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-29 | — | — | US | disclosed |
| EP-2374794-A1 | CYCLIC AMINE COMPOUNDS | Daiichi Sankyo Company, Limited (JP) | 2011-10-12 | — | — | EP | disclosed |
| WO-2010074088-A1 | CYCLIC AMINE COMPOUNDS | 第一三共株式会社 (JP) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360148-A1 | NITRILE SUMO INHIBITORS AND USES THEREOF | SUMO1, SUMO3, SUMO2 | UCHL1 36/4885CHRM2 3910/4885CHRM1 2607/4885 |
| US-12612414-B2 | Nitrile SUMO inhibitors and uses thereof | SUMO1, SUMO3, PSMB6 | UCHL1 60/4885CHRM2 3237/4885CHRM1 2156/4885 |
| US-20120309811-A1 | P-GLYCOPROTEIN-SPECIFIC NON-COMPETITIVE PEPTIDE AND PEPTIDOMIMETIC MODULATORS | ABCB1, ABCG2, SELPLG | UCHL1 4707/4885CHRM2 4700/4885CHRM1 4319/4885 |
| US-20110319468-A1 | CYCLIC AMINE COMPOUNDS | RYR2, CASR, RYR1 | UCHL1 4548/4885CHRM2 252/4885CHRM1 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.